A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
Nick Thatcher
1
,
Fred R. Hirsch
2
,
Aleksandra Szczęsna
3
,
Tudor–Eliade Ciuleanu
4
,
Wojciech Szafrański
5
,
Mircea Dediu
6
,
Rodryg Ramlau
7
,
Rinat Galiulin
8
,
Beatrix Balint
9
,
György Losonczy
10
,
Andrzej Kazarnowicz
11
,
Keunchil Park
12
,
Christian Schumann
13
,
Martin Reck
14
,
Luis Paz-Ares
15
,
Henrik Depenbrock
16
,
Shivani Nanda
17
,
Anamarija Kruljac-Letunic
16
,
Mark A. Socinski
18
1
The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
|
3
Mazowieckie Centrum Leczenia Chorób Pluc, Otwock, Poland
|
4
Institute of Oncology, Cluj-Napoca, Romania
|
5
Department of Respiratory Medicine, Radom District Hospital, Radom, Poland
|
6
Institute of Oncology “Alexandru Trestioreanu”, Bucharest, Romania
|
8
Omsk Regional Oncology Center, Omsk, Russia
|
9
Csongrad County Hospital of Chest Diseases, Deszk, Hungary
|
11
Tuberculosis and Lung Disease Hospital, Olsztyn, Poland
|
12
16
Lilly Deutschland GmBH, Bad Homburg, Germany
|
17
ImClone Systems, Branchburg, NJ
Publication type: Journal Article
Publication date: 2014-05-20
scimago Q1
wos Q1
SJR: 11.205
CiteScore: 38.9
Impact factor: 41.9
ISSN: 0732183X, 15277755
Cancer Research
Oncology
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Memo - Magazine of European Medical Oncology
2 publications, 8.33%
|
|
|
Cochrane Database of Systematic Reviews
2 publications, 8.33%
|
|
|
Expert Opinion on Biological Therapy
2 publications, 8.33%
|
|
|
Clinical Cancer Research
2 publications, 8.33%
|
|
|
American Journal of Respiratory and Critical Care Medicine
1 publication, 4.17%
|
|
|
European Respiratory Review
1 publication, 4.17%
|
|
|
Future Oncology
1 publication, 4.17%
|
|
|
Therapeutic Advances in Respiratory Disease
1 publication, 4.17%
|
|
|
Frontiers in Immunology
1 publication, 4.17%
|
|
|
Cancer and Metastasis Reviews
1 publication, 4.17%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 4.17%
|
|
|
Current Treatment Options in Oncology
1 publication, 4.17%
|
|
|
International Journal of Biological Macromolecules
1 publication, 4.17%
|
|
|
The Lancet Oncology
1 publication, 4.17%
|
|
|
Cancer Treatment and Research
1 publication, 4.17%
|
|
|
Expert Review of Anticancer Therapy
1 publication, 4.17%
|
|
|
Expert Opinion on Emerging Drugs
1 publication, 4.17%
|
|
|
Oncologist
1 publication, 4.17%
|
|
|
Journal not defined
1 publication, 4.17%
|
|
|
Frontiers in Oncology
1 publication, 4.17%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
|
|
|
Springer Nature
6 publications, 25%
|
|
|
Taylor & Francis
4 publications, 16.67%
|
|
|
Frontiers Media S.A.
2 publications, 8.33%
|
|
|
Elsevier
2 publications, 8.33%
|
|
|
Wiley
2 publications, 8.33%
|
|
|
American Association for Cancer Research (AACR)
2 publications, 8.33%
|
|
|
American Thoracic Society
1 publication, 4.17%
|
|
|
European Respiratory Society (ERS)
1 publication, 4.17%
|
|
|
1 publication, 4.17%
|
|
|
SAGE
1 publication, 4.17%
|
|
|
Society for Translational Oncology
1 publication, 4.17%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 4.17%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
24
Total citations:
24
Citations from 2024:
0
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Thatcher N. et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). // Journal of Clinical Oncology. 2014. Vol. 32. No. 15_suppl. p. 8008.
GOST all authors (up to 50)
Copy
Thatcher N., Hirsch F. R., Szczęsna A., Ciuleanu T., Szafrański W., Dediu M., Ramlau R., Galiulin R., Balint B., Losonczy G., Kazarnowicz A., Park K., Schumann C., Reck M., Paz-Ares L., Depenbrock H., Nanda S., Kruljac-Letunic A., Socinski M. A. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). // Journal of Clinical Oncology. 2014. Vol. 32. No. 15_suppl. p. 8008.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1200/jco.2014.32.15_suppl.8008
UR - https://doi.org/10.1200/jco.2014.32.15_suppl.8008
TI - A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
T2 - Journal of Clinical Oncology
AU - Thatcher, Nick
AU - Hirsch, Fred R.
AU - Szczęsna, Aleksandra
AU - Ciuleanu, Tudor–Eliade
AU - Szafrański, Wojciech
AU - Dediu, Mircea
AU - Ramlau, Rodryg
AU - Galiulin, Rinat
AU - Balint, Beatrix
AU - Losonczy, György
AU - Kazarnowicz, Andrzej
AU - Park, Keunchil
AU - Schumann, Christian
AU - Reck, Martin
AU - Paz-Ares, Luis
AU - Depenbrock, Henrik
AU - Nanda, Shivani
AU - Kruljac-Letunic, Anamarija
AU - Socinski, Mark A.
PY - 2014
DA - 2014/05/20
PB - American Society of Clinical Oncology (ASCO)
SP - 8008
IS - 15_suppl
VL - 32
SN - 0732-183X
SN - 1527-7755
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Thatcher,
author = {Nick Thatcher and Fred R. Hirsch and Aleksandra Szczęsna and Tudor–Eliade Ciuleanu and Wojciech Szafrański and Mircea Dediu and Rodryg Ramlau and Rinat Galiulin and Beatrix Balint and György Losonczy and Andrzej Kazarnowicz and Keunchil Park and Christian Schumann and Martin Reck and Luis Paz-Ares and Henrik Depenbrock and Shivani Nanda and Anamarija Kruljac-Letunic and Mark A. Socinski},
title = {A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).},
journal = {Journal of Clinical Oncology},
year = {2014},
volume = {32},
publisher = {American Society of Clinical Oncology (ASCO)},
month = {may},
url = {https://doi.org/10.1200/jco.2014.32.15_suppl.8008},
number = {15_suppl},
pages = {8008},
doi = {10.1200/jco.2014.32.15_suppl.8008}
}
Cite this
MLA
Copy
Thatcher, Nick, et al. “A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)..” Journal of Clinical Oncology, vol. 32, no. 15_suppl, May. 2014, p. 8008. https://doi.org/10.1200/jco.2014.32.15_suppl.8008.